Overview

Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)

Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy and toxicity of pemetrexed and docetaxel administered on a 3-weekly schedule in the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have had prior chemotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Docetaxel
Pemetrexed